Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 4/2020

01-04-2020 | Pancreatic Cancer | Research Article

ILC3 cells promote the proliferation and invasion of pancreatic cancer cells through IL-22/AKT signaling

Authors: X. Xuan, J. Zhou, Z. Tian, Y. Lin, J. Song, Z. Ruan, B. Ni, H. Zhao, W. Yang

Published in: Clinical and Translational Oncology | Issue 4/2020

Login to get access

Abstract

Purpose

Type 3 innate lymphocytes (ILC3s) are reported to be involved in lung cancer, possibly by producing interleukin-22 (IL-22). However, whether ILC3s and their secreted IL-22 molecules contribute to the pathogenesis of pancreatic cancer (PC) remains unclear. To this end, in this study, we investigated the effects and possible mechanisms of ILC3s on PC pathogenesis.

Method

The IL-22 and IL-2i2R levels and the ILC3s’ frequency in cancer tissues from PC patients and in peripheral blood from PC patients and healthy controls were analyzed by flow cytometry, immunochemistry, or immunofluorescence. The effects of IL-22-induced AKT signaling on the proliferation, invasion, and migration of PC cells were examined by co-culturing PC cell lines with ILC3s isolated from PC tissues, with or without the addition of neutralizing IL-22 antibody, IL-22R antibody or AKT inhibitor.

Results

Our results showed that IL-22 and ILC3s were significantly upregulated in the PBMCs and cancer tissues of PC patients, and the IL-22R level was increased in PC cells. The increased frequency of ILC3s was positively correlated with the clinical features of PC patients. Co-culture experiments indicated that ILC3s promoted the proliferation, invasion, and migration of PC cell lines by secreting IL-22 to activate AKT signaling because IL-22/IL-22R or AKT blockage markedly counteracted such effects on PC cells.

Conclusion

Our data demonstrated that ILC3s may promote PC pathogenesis through IL-22/IL-22R-AKT signaling, suggesting a potential intervention target for PC treatment in the future.
Appendix
Available only for authorised users
Literature
1.
Karamitopoulou E, Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features. Br J Cancer 2019.
2.
Nitsche C, et al. Environmental risk factors for chronic pancreatitis and pancreatic cancer. Dig Dis. 2011;29(2):235–42.CrossRef
3.
Dalgleish AG, O'Byrne K. Inflammation and cancer: the role of the immune response and angiogenesis. Cancer Treat Res. 2006;130:1–38.CrossRef
4.
Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117(5):1175–83.CrossRef
5.
Carrega P, et al. NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures. Nat Commun. 2015;6:8280.CrossRef
6.
Spits H, Cupedo T. Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu Rev Immunol. 2012;30:647–75.CrossRef
7.
Artis D, Spits H. The biology of innate lymphoid cells. Nature. 2015;517(7534):293–301.CrossRef
8.
Spits H, et al. Innate lymphoid cells—a proposal for uniform nomenclature. Nat Rev Immunol. 2013;13(2):145–9.CrossRef
9.
Eberl G. Development and evolution of RORgammat+ cells in a microbe's world. Immunol Rev. 2012;245(1):177–88.CrossRef
10.
Chevalier MF, et al. ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. J Clin Invest. 2017;127(8):2916–29.CrossRef
11.
Xuan X, et al. Diverse effects of interleukin-22 on pancreatic diseases. Pancreatology. 2018;18(3):231–7.CrossRef
12.
Sonnenberg GF, Fouser LA, Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol. 2011;12(5):383–90.CrossRef
13.
Curd LM, Favors SE, Gregg RK. Pro-tumour activity of interleukin-22 in HPAFII human pancreatic cancer cells. Clin Exp Immunol. 2012;168(2):192–9.CrossRef
14.
Lin H, et al. Knockdown of OCT4 suppresses the growth and invasion of pancreatic cancer cells through inhibition of the AKT pathway. Mol Med Rep. 2014;10(3):1335–422.CrossRef
15.
Van Maele L, et al. Activation of Type 3 innate lymphoid cells and interleukin 22 secretion in the lungs during Streptococcus pneumoniae infection. J Infect Dis. 2014;210(3):493–503.CrossRef
16.
Montaldo E, Juelke K, Romagnani C. Group 3 innate lymphoid cells (ILC3s): origin, differentiation, and plasticity in humans and mice. Eur J Immunol. 2015;45(8):2171–82.CrossRef
17.
Niccolai E, et al. Intra-tumoral IFN-gamma-producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer. Clin Sci (Lond). 2016;130(4):247–58.CrossRef
18.
Sautes-Fridman C, et al. Tumor microenvironment is multifaceted. Cancer Metastasis Rev. 2011;30(1):13–25.CrossRef
19.
Wolk K, et al. IL-22 increases the innate immunity of tissues. Immunity. 2004;21(2):241–54.CrossRef
20.
Lo YH, et al. Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy. J Dermatol Sci. 2010;58(3):225–7.CrossRef
21.
Zhang L, et al. Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid arthritis. J Clin Immunol. 2011;31(4):606–14.CrossRef
22.
Saalim M, et al. IL-22: a promising candidate to inhibit viral-induced liver disease progression and hepatocellular carcinoma. Tumour Biol. 2016;37(1):105–14.CrossRef
23.
Zhuang Y, et al. Increased intratumoral IL-22-producing CD4(+) T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival. Cancer Immunol Immunother. 2012;61(11):1965–75.CrossRef
24.
Kinnebrew MA, et al. Interleukin 23 production by intestinal CD103(+)CD11b(+) dendritic cells in response to bacterial flagellin enhances mucosal innate immune defense. Immunity. 2012;36(2):276–87.CrossRef
25.
Van Maele L, et al. TLR5 signaling stimulates the innate production of IL-17 and IL-22 by CD3(neg)CD127+ immune cells in spleen and mucosa. J Immunol. 2010;185(2):1177–85.CrossRef
26.
Satpathy AT, et al. Notch2-dependent classical dendritic cells orchestrate intestinal immunity to attaching-and-effacing bacterial pathogens. Nat Immunol. 2013;14(9):937–48.CrossRef
27.
Monticelli LA, et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol. 2011;12(11):1045–54.CrossRef
28.
Taube C, et al. IL-22 is produced by innate lymphoid cells and limits inflammation in allergic airway disease. PLoS ONE. 2011;6(7):e21799.CrossRef
29.
Goto Y, et al. Innate lymphoid cells regulate intestinal epithelial cell glycosylation. Science. 2014;345(6202):1254009.CrossRef
30.
Vivier E, et al. Functions of natural killer cells. Nat Immunol. 2008;9(5):503–10.CrossRef
31.
Neill DR, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010;464(7293):1367–70.CrossRef
32.
Kirchberger S, et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med. 2013;210(5):917–31.CrossRef
33.
Zhao D, et al. Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma. Int J Cancer. 2015;136(11):2556–655.CrossRef
Metadata
Title
ILC3 cells promote the proliferation and invasion of pancreatic cancer cells through IL-22/AKT signaling
Authors
X. Xuan
J. Zhou
Z. Tian
Y. Lin
J. Song
Z. Ruan
B. Ni
H. Zhao
W. Yang
Publication date
01-04-2020
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 4/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02160-5

Other articles of this Issue 4/2020

Clinical and Translational Oncology 4/2020 Go to the issue

Research Article

The effect of fenofibrate, a PPARα activator on toll-like receptor-4 signal transduction in melanoma both in vitro and in vivo

Research Article

Single hormone receptor-positive breast cancer patients experienced poor survival outcomes: a systematic review and meta-analysis

Review Article

Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients

Research Article

First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial

Research Article

Resection of liver metastases from breast cancer: a multicentre analysis

Research Article

Red and processed meat consumption and esophageal cancer risk: a systematic review and meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits